The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 344:1411-1420 May 10, 2001 Number 19
NextNext

Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
Allan L. Klein, M.D., Richard A. Grimm, D.O., R. Daniel Murray, Ph.D., Carolyn Apperson-Hansen, M.Stat., Richard W. Asinger, M.D., Ian W. Black, M.D., Ravin Davidoff, M.B., B.Ch., Raimund Erbel, M.D., Jonathan L. Halperin, M.D., David A. Orsinelli, M.D., Thomas R. Porter, M.D., Marcus F. Stoddard, M.D., for the Assessment of Cardioversion Using Transesophageal Echocardiography Investigators

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Silverman, D. I.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background The conventional treatment strategy for patients with atrial fibrillation who are to undergo electrical cardioversion is to prescribe warfarin for anticoagulation for three weeks before cardioversion. It has been proposed that if transesophageal echocardiography reveals no atrial thrombus, cardioversion may be performed safely after only a short period of anticoagulant therapy.

Methods In a multicenter, randomized, prospective clinical trial, we enrolled 1222 patients with atrial fibrillation of more than two days' duration and assigned them to either treatment guided by the findings on transesophageal echocardiography or conventional treatment. The composite primary end point was cerebrovascular accident, transient ischemic attack, and peripheral embolism within eight weeks. Secondary end points were functional status, successful restoration and maintenance of sinus rhythm, hemorrhage, and death.

Results There was no significant difference between the two treatment groups in the rate of embolic events (five embolic events among 619 patients in the transesophageal-echocardiography group [0.8 percent]) vs. three among 603 patients in the conventional-treatment group [0.5 percent], P=0.50). However, the rate of hemorrhagic events was significantly lower in the transesophageal-echocardiography group (18 events [2.9 percent] vs. 33 events [5.5 percent], P=0.03). Patients in the transesophageal-echocardiography group also had a shorter time to cardioversion (mean [±SD], 3.0±5.6 vs. 30.6±10.6 days; P<0.001) and a greater rate of successful restoration of sinus rhythm (440 patients [71.1 percent] vs. 393 patients [65.2 percent], P=0.03). At eight weeks, there were no significant differences between the two groups in the rates of death or maintenance of sinus rhythm or in functional status.

Conclusions The use of transesophageal echocardiography to guide the management of atrial fibrillation may be considered a clinically effective alternative strategy to conventional therapy for patients in whom elective cardioversion is planned.


Source Information

From the Cleveland Clinic Foundation, Cleveland (A.L.K., R.A.G., R.D.M., C.A.-H.); Hennepin County Medical Center, Minneapolis (R.W.A.); Manly Hospital, Manly, N.S.W., Australia (I.W.B.); Boston Medical Center, Boston (R.D.); Universitätsklinikum–Essen, Essen, Germany (R.E.); Mount Sinai School of Medicine, New York (J.L.H.); Ohio State University, Columbus (D.A.O.); the University of Nebraska, Omaha (T.R.P.); and the University of Louisville, Louisville, Ky. (M.F.S.).

Address reprint requests to Dr. Klein at the Cleveland Clinic Foundation, 9500 Euclid Ave., Department of Cardiology — Desk F15, Cleveland, OH 44195, or at kleina{at}ccf.org.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.